Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Other Non-Cash Items history
Currency unavailable · from the cash flow
No Other Non-Cash Items data reported for this period type.
Other Non-Cash Items vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $44.04M USD | +20871.7% | +213.8% | — | |
| LTM Mar 2026 | $8.35M USD | +500.3% | — | — | |
| LTM Mar 2026 | $3.74M USD | +252.3% | — | 1.7% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $2.01M USD | — | -33.1% | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.66M USD | +167.4% | -60.9% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.03M USD | +118.7% | -50.7% | 5.2% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $562K USD | +183.4% | -52.2% | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | +217.9% | -50.7% | 3.4% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.